🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

HANDLE-a Real World Study on Satralizumab in NMOSD

Recruitingn/aAges 12 Years - anyAllHuashan Hospital
NCT06829524 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study is a single-center, retrospective-prospective, non-interventional cohort study to assess the clinical outcomes of Chinese NMOSD patients treated with satralizumab in a real-world patient management model by collecting follow-up data in clinical practice.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Patients have been diagnosed with NMOSD and tested seropositive for AQP4 antibody, ≥ 12 years old; 2. EDSS score ≤ 8.5 at baseline; 3. Patients have experienced ≥ 1 relapse of NMOSD in the last 12 months or ≥ 2 relapses in the last 24 months; 4. Patients should have received or be anticipated to receive satralizumab treatment for at least 12 months; 5. Patients understand the study procedures and sign the informed consent form indicating willingness to participate in the study (for those \< 18 years of age, the guardian should sign the informed consent form on behalf of the patient). Exclusion Criteria: \-
💊

What it tests

  • Satralizumab
📍

Where

1 site
Huashan Hospital
Shanghai, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy